Genomic, biochemical, and cellular drivers of brain tumor heterogeneity and evolution. Cancer predisposition syndromes. Response and resistance to treatment.
Wonderful to see this work published, which establishes a new prospective, consecutive benchmark for the population prevalence of molecular alterations in #meningioma. Critical for design of molecularly-guided clinical trials. @UCSFRadOnc@UCSF@UCSFCancer@NeurosurgUCSF
In a new @JAMAOnc study, @LabRaleigh and colleagues report the results from a prospective genomic profiling analysis of more than 1100 meningiomas. Their findings could help guide evolving diagnostic criteria and clinical trial design: jamanetwork.com/journals/jam…@UCSFRadOnc
ALT Graphic showing an MRI scan of a meningioma. Text banner with the publication citation reads, Prospective Genomic Profiling of Consecutive Meningiomas. Nguyen MP, Mirchia K, Braman BC, et al. (2026) JAMA Oncol.
Congratulations to David @LabRaleigh on being appointed Translational Science Co-Vice Chair of the NRG Brain Tumor Committee! @NeurosurgUCSF@UCSF@NRGonc
David Raleigh, MD, PhD, presenting data from @LabRaleigh on genomic profiling of over 1000 consecutive, prospective meningiomas to a full house at #SNO2025. Understanding the molecular alterations of these tumors is leading to better biomarkers of treatment response.
Grateful to the many teams who supported this work, championed by Karenna Groff. As we uncover more biomarkers of tumor behavior, implementation into clinical practice merits close introspection of context. @MGBneurosurgery@LabRaleigh@sahm_lab@MGBCTNS@NYUneurosurgery@RuchitVP
One of the most discussed topics in neurosurgery: The Rationale for Early Adjuvant Radiotherapy After Gross... : Neurosurgery journals.lww.com/neurosurger…